IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Clinical trial NCT05805956 · UNKNOWN

Trial details

NCT number: NCT05805956
Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Advanced Lung Cancer Advanced Gastric Carcinoma Advanced Cholangiocarcinoma

Start date: 2022-02-15
Primary completion: 2024-10-01
Enrollment: 105

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.